LSAT 141 – Section 4 – Question 06

LSAT 141 - Section 4 - Question 06

September 2014

You need a full course to see this video. Enroll now and get started in less than a minute.

Request new explanation

Target time: 0:57

This is question data from the 7Sage LSAT Scorer. You can score your LSATs, track your results, and analyze your performance with pretty charts and vital statistics - all with a Free Account ← sign up in less than 10 seconds

Question
QuickView		 Type Tags Answer
Choices		 Curve Question
Difficulty		 Psg/Game/S
Difficulty		 Explanation
PT141 S4 Q06
+LR
Evaluate +Eval
Causal Reasoning +CausR
A
0%
148
B
1%
151
C
0%
154
D
1%
161
E
97%
163
120
126
137
 +Easiest 147.542 +SubsectionMedium

Clinician: Patients with immune system disorders are usually treated with a class of drugs that, unfortunately, increase the patient’s risk of developing osteoporosis, a bone-loss disease. So these patients take another drug that helps to preserve existing bone. Since a drug that enhances the growth of new bone cells has now become available, these patients should take this new drug in addition to the drug that helps to preserve existing bone.

Summarize Argument
The clinician concludes that patients with immune system disorders should take a new bone-growth drug in addition their bone-preservation drug. This is because that drug enhances the growth of new bone cells, and patients with immune system disorders are at risk of a bone-loss disease.

Notable Assumptions
The clinician assumes that the two drugs—bone-growth and bone-preservation—are fine to take together. This means she doesn’t believe the two drugs would interfere with one another, or that there would be some health risk to taking them together. She also believes that these patients should take a drug stimulating bone growth simply because they’re at risk of osteoporosis. This means she doesn’t believe that osteoporosis has to have developed for the bone-growth drug to be useful.

A
How large is the class of drugs that increase the risk of developing osteoporosis?
We don’t care how large that class of drugs is. We care about what someone taking such drugs should do.
B
Why are immune system disorders treated with drugs that increase the risk of developing osteoporosis?
Irrelevant. The clinician’s conclusion is about what should be done to address the risk of osteoporosis, rather than why osteoporosis develops in the first place.
C
Is the new drug more expensive than the drug that helps to preserve existing bone?
Price is beside the point. The clinician is recommending the best medical course of action to address the risk of osteoporosis.
D
How long has the drug that helps to preserve existing bone been in use?
We’re not interested in the bone-preservation drug. We have no idea what its history would even reveal about its efficacy.
E
To what extent does the new drug retain its efficacy when used in combination with the other drugs?
If the new drug doesn’t retain its efficacy in combination with the other drugs, then there’s no point in patients taking it. On the other hand, if it does retain its efficacy, then the clinician’s argument is strengthened: the drugs don’t have undesired effects in combination.

Take PrepTest

Review Results

LSAT PrepTest 141 Explanations

Section 1 - Reading Comprehension

Section 2 - Logical Reasoning

Section 3 - Reading Comprehension

Section 4 - Logical Reasoning

Get full LSAT course

Leave a Reply